About Laura Tadvalkar
Laura Tadvalkar, PhD, is a managing director on the venture team at RA Capital Management, which co-led Typewriter's Series A. She sits on the boards of Typewriter Therapeutics, GIVAX, Imbria Pharmaceuticals, NorthLinks Bio and Serapha Bio.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Laura Tadvalkar in the role, so the role may have started earlier or lasted longer.
Typewriter Therapeutics, Inc. Current
Director
2026 – Present · Cambridge, MA
Typewriter Therapeutics develops all-RNA medicines that insert a full working gene at a natural safe harbor site in the genome, starting with in vivo CAR-T.
RM
RA Capital Management Current
Managing Director, Venture
AT
Aliada Therapeutics
Board Chair
MO
Mariana Oncology
Board Director
MM
MP Healthcare Venture Management
Principal
CH
Clarion Healthcare
Consultant
GI
GIVAX
Board member
IP
Imbria Pharmaceuticals
Board member
NB
NorthLinks Bio
Board member
SB
Serapha Bio
Board member
Education
- BS, Chemistry, Yale University
- PhD, Chemical Biology, Harvard University
Key Colleagues at Startups
The people Laura Tadvalkar works with at each company, as listed on that company's latest Form D.
Typewriter Therapeutics, Inc. · Form D, Sep 21, 2026
MS
Matthew Stanton
Chief Executive Officer and Board Director
KH
Kenneth Horne
Director
MD
Mikael Dolsten
Independent Board Director